Chronic Moderate Sleep Restriction in Older Adults

Aging Clinical Trial

— MSSS  

Official title:

Chronic Moderate Sleep Restriction in Older Long Sleepers and Older Average Sleepers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01642719
• Other study ID #: 1R01HL095799-01A2
• Secondary ID: 1R01HL095799-01A
• Status: Completed
• Phase: Phase 1
• Start date: July 1, 2012
• Est. completion date: December 2018

Study information

• Verified date: July 2019
• Source: University of California, Los Angeles
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Higher rates of mortality have been found both in short sleepers (< 6 hr/night) and long sleepers (> 8 hr/night), but there has been little experimental investigation of the effects of chronic, moderate sleep loss in long or average sleepers. Some scientists argue that older adults might be particularly vulnerable to negative effects of sleep loss, whereas other scientists argue that many older adults spend too much time in bed, and that moderate reduction of time-in-bed could help increase the quality of their sleep, and could even promote health and longevity, particularly in long sleepers. At 4 sites across the US, we will conduct a large (200 people), randomized, controlled, 5- year study to examine whether a 1-hour reduction of time spent in bed for 12 weeks has negative or positive effects on multiple health-related outcomes, including inflammation, sleepiness, body weight, mood, glucose regulation, quality of life, incidence of illness, and incidence of automobile accidents in older long sleepers as compared to older average sleepers.

Description:

Epidemiologic studies have consistently shown that self -reported sleep durations of <7 hr and >8 hr are associated with increased mortality and morbidity. The risks associated with short sleep are consistent with a vast experimental literature indicating detrimental effects of profound sleep restriction. However, there has been little study of chronic moderate sleep restriction, which is far more common, and thus more important from a public health standpoint. The risks associated with long sleep have scarcely been experimentally examined, though epidemiological data suggest sleep restriction might promote health/longevity in long sleepers. Older adults might be more vulnerable than young adults to negative effects of further sleep impairment, perhaps particularly via inflammatory mechanisms. Negative effects might be at least as evident in long sleepers as in average sleepers if long sleep reflects underlying morbidity, as many have posited. On the other hand, older adults might tolerate (or benefit) from moderate sleep restriction. Older adults often tend to spend excessive time in bed (TIB), particularly long sleepers, and extra TIB could contribute to age-related sleep fragmentation and morbidity, which could be ameliorated with modest TIB restriction. The aims of this study are: (1) to examine the ability of older long sleepers and older average sleepers to adhere to 60 min TIB restriction; and (2) to contrast effects of 12 weeks of 60 min TIB restriction on health-related measures in older long vs. average sleepers. One hundred older adults (ages 60-80 yr) who report sleeping 8-9 hr per night and 100 adults of the same age range who report sleeping 6-7.25 hr per night will be examined at 4 experimental sites over 5 years. Following a 2-week baseline, participants will be randomly assigned to one of two 12-week treatment groups. (1) A sleep restriction group (n=60 long sleepers and n=60 average sleepers) will be assigned to a fixed sleep- wake schedule, in which time in bed is reduced precisely 60 min below each participant's baseline time in bed (TIB). (2) A control group (n=40 long sleepers and n=40 average sleepers) will have no sleep restriction, but will also follow a fixed sleep schedule. Sleep will be assessed continuously with actigraphy and a daily diary. Questionnaires will be answered. Measures will include body weight, glucose tolerance, sleepiness, depression, quality of life, psychomotor vigilance, incidence of automobile accidents, incidence of illness, and multiple markers of inflammation. Physical exams during weeks 2 and 6 of the intervention and a study ombudsman will further monitor potential adverse effects. Follow-up assessments will be conducted for 12 months. The proposed clinical trial will provide the most comprehensive Phase 1 assessment of risks and benefits of chronic moderate TIB restriction ever conducted.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: December 2018
• Est. primary completion date: August 1, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Years to 80 Years

Eligibility

Inclusion Criteria:

• 60-80 years of age

• Sleeping an average of 8-9 hr per night for long sleeper (or)

• Sleep an average of 6.0-7.25 hr per night for short sleepers

• Able to designate a study partner that can speak on their behalf throughout the course of the study.

Exclusion Criteria:

• Reported average sleep duration of < 8.0 hr or > 9.0 hr for longer sleepers

• Reported average sleep duration of < 6 hr or > 7.25 hr for the average sleepers

• Spending > 30 min time in bed in the morning and/or night outside of the major sleep period (e.g., watching tv)

• Expected change in usual sleep duration in the near future (e.g., change in work schedule)

• Reported average napping of > 2 naps/day or total nap duration of > 90 min/day;

• Recent shift-work (previous 2 months) or travel across multiple time zones (previous 4 weeks), or plans for performing shift-work or transmeridian travel during the study time period;

• Severe sleep apnea (apnea-hyponea index of greater or equal 15);

• Obesity (body mass index =35);

• High daytime sleepiness (Epworth Sleepiness Scale = 10);

• Depression (Quick Inventory of Depressive Sympotomology > or equal to 16);

• Use of hypnotics or other drugs prescribed to promote sleep;

• Alcohol dependence or drug use;

• Any medical, neurologic, or psychiatric illness causing long sleep;

• Factors associated with significant changes in inflammation, including several medical disorders (e.g., rheumatoid arthritis), medications (e.g., steroids) and current smoking;

• Any health or mental condition that would contraindicate participation in the rigors of the study

Related Conditions & MeSH terms

• Aging
• Dyssomnias
• Parasomnias
• Sleep Disturbance
• Sleep Wake Disorders

Intervention

Behavioral:
• Sleep restriction
Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks.
• Non-sleep restriction
Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline.

Locations

Country	Name	City	State
United States	SUNY Downstate Medical Center	Brooklyn	New York
United States	University of South Carolina	Columbia	South Carolina
United States	UCLA Cousins Center for Psychoneuroimmunology	Los Angeles	California
United States	University of Arizona	Tucson	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
University of California, Los Angeles	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in adherence to sleep restriction from baseline	Evaluation of ability to adhere to a 60 min time-in-bed restriction over 12 weeks	Daily for 12 weeks
Secondary	Change in sleepiness from baseline	Evaluation of sleepiness by weekly self-report for 12 weeks	Every week for 12 weeks
Secondary	Change in health functioning from baseline	Evaluation of health functioning by self-report for 12 weeks	Every 2 weeks for 12 weeks
Secondary	Change in sleep quality from baseline	Evaluation of sleep quality by self report every month for 12 weeks	Every month for 12 weeks
Secondary	Change in measures of cognitive performance from baseline	Evaluation of cognitive performance including standardized tasks to assess attention every month for 12 weeks	Every month for 12 weeks
Secondary	Change in physical activity from baseline	Evaluation of physical activity by waist actigraphy and self-report every 8 weeks for 12 weeks	Every 8 weeks for 12 weeks
Secondary	Markers of glucose metabolism	Evaluation of glucose metabolism by fasting glucose, glucose tolerance test, and hemoglobin A1C at baseline and again at 12 weeks	Baseline and at 12 weeks
Secondary	Change in depressive symptoms from baseline	Evaluation of depressive symptoms by self-report every 2 weeks for 12 weeks	Every 2 weeks for 12 weeks
Secondary	Markers of inflammation	Evaluation of cellular and genomic markers of inflammation at baseline and at 12 weeks	Baseline and at 12 weeks
Secondary	Change in fatigue from baseline	Evaluation of fatigue by self-report every 2 weeks for 12 weeks	Every 2 weeks for 12 weeks

External Links

•   UCLA Cousins Center for Psychoneuroimmunology